Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer

Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum in...

Full description

Saved in:
Bibliographic Details
Published inSignal transduction and targeted therapy Vol. 6; no. 1; pp. 398 - 10
Main Authors Gao, Yaohui, Bi, Dexi, Xie, Ruting, Li, Man, Guo, Jing, Liu, Hu, Guo, Xianling, Fang, Juemin, Ding, Tingting, Zhu, Huiyuan, Cao, Yuan, Xing, Meichun, Zheng, Jiayi, Xu, Qing, Xu, Qian, Wei, Qing, Qin, Huanlong
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 19.11.2021
Nature Publishing Group
Subjects
692/53/2422
692/699/67/1504
Antitumor activity
Cancer
Cancer Research
CD8 antigen
Cell Biology
Colorectal cancer
Colorectal carcinoma
Fusobacterium nucleatum
Immune checkpoint
Immune response
Immunotherapy
Internal Medicine
Lymphocytes
Medicine
Medicine & Public Health
Oncology
Organoids
Pathology
Patients
PD-1 protein
PD-L1 protein
Supplements
Tumor-infiltrating lymphocytes
γ-Interferon
Online AccessGet full text

Cover

Abstract Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum induces different immune responses in CRC with different microsatellite-instability (MSI) statuses. Here, we investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC. We found that high F. nucleatum levels correlate with improved therapeutic responses to PD-1 blockade in patients with CRC. Additionally, F. nucleatum enhanced the antitumor effects of PD-L1 blockade on CRC in mice and prolonged survival. Combining F. nucleatum supplementation with immunotherapy rescued the therapeutic effects of PD-L1 blockade. Furthermore, F. nucleatum induced PD-L1 expression by activating STING signaling and increased the accumulation of interferon-gamma (IFN-γ) + CD8 + tumor-infiltrating lymphocytes (TILs) during treatment with PD-L1 blockade, thereby augmenting tumor sensitivity to PD-L1 blockade. Finally, patient-derived organoid models demonstrated that increased F. nucleatum levels correlated with an improved therapeutic response to PD-L1 blockade. These findings suggest that F. nucleatum may modulate immune checkpoint therapy for CRC.
AbstractList Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum induces different immune responses in CRC with different microsatellite-instability (MSI) statuses. Here, we investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC. We found that high F. nucleatum levels correlate with improved therapeutic responses to PD-1 blockade in patients with CRC. Additionally, F. nucleatum enhanced the antitumor effects of PD-L1 blockade on CRC in mice and prolonged survival. Combining F. nucleatum supplementation with immunotherapy rescued the therapeutic effects of PD-L1 blockade. Furthermore, F. nucleatum induced PD-L1 expression by activating STING signaling and increased the accumulation of interferon-gamma (IFN-γ)+ CD8+ tumor-infiltrating lymphocytes (TILs) during treatment with PD-L1 blockade, thereby augmenting tumor sensitivity to PD-L1 blockade. Finally, patient-derived organoid models demonstrated that increased F. nucleatum levels correlated with an improved therapeutic response to PD-L1 blockade. These findings suggest that F. nucleatum may modulate immune checkpoint therapy for CRC.
Abstract Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum induces different immune responses in CRC with different microsatellite-instability (MSI) statuses. Here, we investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC. We found that high F. nucleatum levels correlate with improved therapeutic responses to PD-1 blockade in patients with CRC. Additionally, F. nucleatum enhanced the antitumor effects of PD-L1 blockade on CRC in mice and prolonged survival. Combining F. nucleatum supplementation with immunotherapy rescued the therapeutic effects of PD-L1 blockade. Furthermore, F. nucleatum induced PD-L1 expression by activating STING signaling and increased the accumulation of interferon-gamma (IFN-γ)+ CD8+ tumor-infiltrating lymphocytes (TILs) during treatment with PD-L1 blockade, thereby augmenting tumor sensitivity to PD-L1 blockade. Finally, patient-derived organoid models demonstrated that increased F. nucleatum levels correlated with an improved therapeutic response to PD-L1 blockade. These findings suggest that F. nucleatum may modulate immune checkpoint therapy for CRC.
Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum induces different immune responses in CRC with different microsatellite-instability (MSI) statuses. Here, we investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC. We found that high F. nucleatum levels correlate with improved therapeutic responses to PD-1 blockade in patients with CRC. Additionally, F. nucleatum enhanced the antitumor effects of PD-L1 blockade on CRC in mice and prolonged survival. Combining F. nucleatum supplementation with immunotherapy rescued the therapeutic effects of PD-L1 blockade. Furthermore, F. nucleatum induced PD-L1 expression by activating STING signaling and increased the accumulation of interferon-gamma (IFN-γ) CD8 tumor-infiltrating lymphocytes (TILs) during treatment with PD-L1 blockade, thereby augmenting tumor sensitivity to PD-L1 blockade. Finally, patient-derived organoid models demonstrated that increased F. nucleatum levels correlated with an improved therapeutic response to PD-L1 blockade. These findings suggest that F. nucleatum may modulate immune checkpoint therapy for CRC.
Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum induces different immune responses in CRC with different microsatellite-instability (MSI) statuses. Here, we investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC. We found that high F. nucleatum levels correlate with improved therapeutic responses to PD-1 blockade in patients with CRC. Additionally, F. nucleatum enhanced the antitumor effects of PD-L1 blockade on CRC in mice and prolonged survival. Combining F. nucleatum supplementation with immunotherapy rescued the therapeutic effects of PD-L1 blockade. Furthermore, F. nucleatum induced PD-L1 expression by activating STING signaling and increased the accumulation of interferon-gamma (IFN-γ) + CD8 + tumor-infiltrating lymphocytes (TILs) during treatment with PD-L1 blockade, thereby augmenting tumor sensitivity to PD-L1 blockade. Finally, patient-derived organoid models demonstrated that increased F. nucleatum levels correlated with an improved therapeutic response to PD-L1 blockade. These findings suggest that F. nucleatum may modulate immune checkpoint therapy for CRC.
Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum induces different immune responses in CRC with different microsatellite-instability (MSI) statuses. Here, we investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC. We found that high F. nucleatum levels correlate with improved therapeutic responses to PD-1 blockade in patients with CRC. Additionally, F. nucleatum enhanced the antitumor effects of PD-L1 blockade on CRC in mice and prolonged survival. Combining F. nucleatum supplementation with immunotherapy rescued the therapeutic effects of PD-L1 blockade. Furthermore, F. nucleatum induced PD-L1 expression by activating STING signaling and increased the accumulation of interferon-gamma (IFN-γ)+ CD8+ tumor-infiltrating lymphocytes (TILs) during treatment with PD-L1 blockade, thereby augmenting tumor sensitivity to PD-L1 blockade. Finally, patient-derived organoid models demonstrated that increased F. nucleatum levels correlated with an improved therapeutic response to PD-L1 blockade. These findings suggest that F. nucleatum may modulate immune checkpoint therapy for CRC.Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum induces different immune responses in CRC with different microsatellite-instability (MSI) statuses. Here, we investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC. We found that high F. nucleatum levels correlate with improved therapeutic responses to PD-1 blockade in patients with CRC. Additionally, F. nucleatum enhanced the antitumor effects of PD-L1 blockade on CRC in mice and prolonged survival. Combining F. nucleatum supplementation with immunotherapy rescued the therapeutic effects of PD-L1 blockade. Furthermore, F. nucleatum induced PD-L1 expression by activating STING signaling and increased the accumulation of interferon-gamma (IFN-γ)+ CD8+ tumor-infiltrating lymphocytes (TILs) during treatment with PD-L1 blockade, thereby augmenting tumor sensitivity to PD-L1 blockade. Finally, patient-derived organoid models demonstrated that increased F. nucleatum levels correlated with an improved therapeutic response to PD-L1 blockade. These findings suggest that F. nucleatum may modulate immune checkpoint therapy for CRC.
Author Xing, Meichun
Wei, Qing
Zheng, Jiayi
Xu, Qian
Li, Man
Gao, Yaohui
Liu, Hu
Guo, Xianling
Fang, Juemin
Zhu, Huiyuan
Xie, Ruting
Qin, Huanlong
Bi, Dexi
Ding, Tingting
Xu, Qing
Guo, Jing
Cao, Yuan
Author_xml – sequence: 1
  givenname: Yaohui
  surname: Gao
  fullname: Gao, Yaohui
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 2
  givenname: Dexi
  surname: Bi
  fullname: Bi, Dexi
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 3
  givenname: Ruting
  surname: Xie
  fullname: Xie, Ruting
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 4
  givenname: Man
  surname: Li
  fullname: Li, Man
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 5
  givenname: Jing
  surname: Guo
  fullname: Guo, Jing
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 6
  givenname: Hu
  surname: Liu
  fullname: Liu, Hu
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 7
  givenname: Xianling
  surname: Guo
  fullname: Guo, Xianling
  organization: Department of Oncology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 8
  givenname: Juemin
  surname: Fang
  fullname: Fang, Juemin
  organization: Department of Oncology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 9
  givenname: Tingting
  surname: Ding
  fullname: Ding, Tingting
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 10
  givenname: Huiyuan
  surname: Zhu
  fullname: Zhu, Huiyuan
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 11
  givenname: Yuan
  surname: Cao
  fullname: Cao, Yuan
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 12
  givenname: Meichun
  surname: Xing
  fullname: Xing, Meichun
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 13
  givenname: Jiayi
  surname: Zheng
  fullname: Zheng, Jiayi
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 14
  givenname: Qing
  surname: Xu
  fullname: Xu, Qing
  organization: Department of Oncology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 15
  givenname: Qian
  surname: Xu
  fullname: Xu, Qian
  organization: Department of Gastrointestinal Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 16
  givenname: Qing
  surname: Wei
  fullname: Wei, Qing
  email: weiqing1971@tongji.edu.cn
  organization: Department of Pathology, Shanghai Tenth People’s Hospital Affiliated to Tongji University
– sequence: 17
  givenname: Huanlong
  surname: Qin
  fullname: Qin, Huanlong
  email: qinhuanlong@tongji.edu.cn
  organization: Department of Gastrointestinal Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34795206$$D View this record in MEDLINE/PubMed
BookMark eNpdUk1v1DAQtVARbZf-AQ4oEhcuAX8nviChQkulleBQztbEnuxmydrFTqr23-N0y0c5eTzz5nme552SoxADEvKK0XeMivZ9lkwYXlPOakobo-q7Z-SEU2VqoYU6WuKSNIY2x-Qs5x2llGnRNEq-IMdClg5O9Qm5vphz7MBNmIZ5X4XZjQhTiTBsITjM1bTFCvt-cODuq9hX3z7Va1Z1Y3Q_wGM1hMrFMSZ0E4yVW3rSS_K8hzHj2eO5It8vPl-ff6nXXy-vzj-ua6-YnGrHW9DKK0UBuVCa6rYo0Ro8tFxp30pnQDKA3qChHUejOuWN95r2XisUK3J14PURdvYmDXtI9zbCYB8SMW0spGkokqwy1EmmpSnKpZbCqPKKoh49YLnqwvXhwHUzd3v0DsOUYHxC-rQShq3dxFvbasolawrB20eCFH_OmCe7H7LDcYSAcc6WK2NYY9pWFOib_6C7OKdQvmpBLQhdtrsir_-d6M8ov5dXAOIAyKUUNpj-0jBqF5fYg0tscYl9cIm9E78A0ByuTA
Cites_doi 10.1002/jcb.27329
10.15252/embj.2018100983
10.1021/acs.nanolett.0c01140
10.1038/nrurol.2016.103
10.1038/d41586-018-05208-8
10.1158/2326-6066.CIR-18-0174
10.1126/science.aac4255
10.1126/science.aao5610
10.1016/j.cell.2017.07.008
10.1101/gr.126516.111
10.1126/science.aan3706
10.1158/1078-0432.CCR-16-1786
10.1016/j.ccell.2015.03.001
10.1053/j.gastro.2016.11.018
10.1038/nature13904
10.1038/sj.cgt.7700634
10.1038/s41598-017-18596-0
10.1038/s41586-019-1593-5
10.1126/scitranslmed.aak9537
10.1158/1078-0432.CCR-15-1125
10.1016/j.chom.2013.07.012
10.1038/d41586-017-08699-z
10.1056/NEJMoa1507643
10.1038/s41575-019-0126-x
10.1016/j.canlet.2019.10.033
10.1084/jem.20192282
10.1016/j.chom.2016.07.006
10.1021/acs.jmedchem.9b01039
10.1158/1078-0432.CCR-15-1678
10.1200/JCO.2002.20.1.142
10.1038/s41586-019-0878-z
10.1056/NEJMoa1305133
10.1136/gutjnl-2015-310101
ContentType Journal Article
Copyright The Author(s) 2021. corrected publication 2021
2021. The Author(s).
The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021, corrected publication 2021
Copyright_xml – notice: The Author(s) 2021. corrected publication 2021
– notice: 2021. The Author(s).
– notice: The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021, corrected publication 2021
DBID C6C
NPM
3V.
7T5
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1038/s41392-021-00795-x
DatabaseName Springer Nature OA Free Journals
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 2059-3635
EndPage 10
ExternalDocumentID oai_doaj_org_article_590c41649479464395ada50dedae6436
PMC8602417
34795206
10_1038_s41392_021_00795_x
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission)
  grantid: 20ZR1442800
  funderid: https://doi.org/10.13039/501100003399
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 81972221; 8177100280; 81730102; 81702037
  funderid: https://doi.org/10.13039/501100001809
– fundername: ;
  grantid: 81972221; 8177100280; 81730102; 81702037
– fundername: ;
  grantid: 20ZR1442800
GroupedDBID 0R~
3V.
5VS
7X7
8FI
8FJ
AAJSJ
ABUWG
ACGFS
ACSMW
ADBBV
AFKRA
AJTQC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
EBLON
EBS
EJD
EMOBN
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
M7P
NAO
OK1
PIMPY
PQQKQ
PROAC
RNT
RPM
SNYQT
UKHRP
NPM
7T5
7XB
8FE
8FH
8FK
AARCD
AASML
AZQEC
DWQXO
GNUQQ
H94
K9.
LK8
PHGZM
PHGZT
PKEHL
PQEST
PQGLB
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-d514t-c28a65d550ae235606807966ada8256d84c9a41aaf9e90b2e95b5d9dd60fd65e3
IEDL.DBID C6C
ISSN 2095-9907
2059-3635
IngestDate Wed Aug 27 01:28:12 EDT 2025
Thu Aug 21 18:45:37 EDT 2025
Fri Jul 11 12:23:22 EDT 2025
Wed Aug 13 04:19:05 EDT 2025
Thu Jan 02 22:57:20 EST 2025
Fri Feb 21 02:39:11 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2021. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-d514t-c28a65d550ae235606807966ada8256d84c9a41aaf9e90b2e95b5d9dd60fd65e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.nature.com/articles/s41392-021-00795-x
PMID 34795206
PQID 2598833641
PQPubID 2041911
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_590c41649479464395ada50dedae6436
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8602417
proquest_miscellaneous_2599179883
proquest_journals_2598833641
pubmed_primary_34795206
springer_journals_10_1038_s41392_021_00795_x
PublicationCentury 2000
PublicationDate 2021-11-19
PublicationDateYYYYMMDD 2021-11-19
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-19
  day: 19
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Signal transduction and targeted therapy
PublicationTitleAbbrev Sig Transduct Target Ther
PublicationTitleAlternate Signal Transduct Target Ther
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Castellarin (CR15) 2012; 22
Tanoue (CR24) 2019; 565
Zhou (CR30) 2020; 20
Mima (CR19) 2016; 65
Routy (CR11) 2018; 359
Ganesh (CR7) 2019; 16
Demaria (CR22) 2019; 574
Abed (CR16) 2016; 20
Stempel (CR27) 2019; 38
Zhang, You, Xu (CR28) 2020; 63
Shi (CR29) 2020; 217
Nemunaitis (CR35) 2003; 10
Rubinstein (CR17) 2013; 14
Dudley, Lin, Le, Eshleman (CR21) 2016; 22
Yang (CR18) 2017; 152
Li (CR25) 2018; 119
Fu (CR26) 2015; 7
Yang (CR33) 2017; 358
Borghaei (CR3) 2015; 373
Hamada (CR20) 2018; 6
Gao (CR36) 2019; 42
Powles (CR5) 2014; 515
Topalian, Drake, Pardoll (CR2) 2015; 27
Guo (CR32) 2020; 469
Loi (CR23) 2016; 22
Yu (CR9) 2017; 170
Sivan (CR10) 2015; 350
Toso (CR34) 2002; 20
Hamid (CR4) 2013; 369
Carlo, Voss, Motzer (CR6) 2016; 13
Zheng (CR31) 2017; 9
Hsieh (CR14) 2018; 8
Bender (CR1) 2017; 552
Guglielmi (CR8) 2018; 557
Signat, Roques, Poulet, Duffaut (CR12) 2011; 13
Yamamura (CR13) 2016; 22
34934043 - Signal Transduct Target Ther. 2021 Dec 21;6(1):434
References_xml – volume: 119
  start-page: 9997
  year: 2018
  end-page: 10004
  ident: CR25
  article-title: LPS promotes the expression of PD-L1 in gastric cancer cells through NF-kappaB activation
  publication-title: J. Cell Biochem.
  doi: 10.1002/jcb.27329
– volume: 38
  start-page: e100983
  year: 2019
  ident: CR27
  article-title: The herpesviral antagonist m152 reveals differential activation of STING-dependent IRF and NF-kappaB signaling and STING’s dual role during MCMV infection
  publication-title: EMBO J
  doi: 10.15252/embj.2018100983
– volume: 20
  start-page: 4393
  year: 2020
  end-page: 4402
  ident: CR30
  article-title: Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer
  publication-title: Nano Lett.
  doi: 10.1021/acs.nanolett.0c01140
– volume: 13
  start-page: 420
  year: 2016
  end-page: 431
  ident: CR6
  article-title: Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
  publication-title: Nat. Rev. Urol.
  doi: 10.1038/nrurol.2016.103
– volume: 557
  start-page: 482
  year: 2018
  end-page: 484
  ident: CR8
  article-title: How gut microbes are joining the fight against cancer
  publication-title: Nature
  doi: 10.1038/d41586-018-05208-8
– volume: 6
  start-page: 1327
  year: 2018
  end-page: 1336
  ident: CR20
  article-title: Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status
  publication-title: Cancer Immunol. Res
  doi: 10.1158/2326-6066.CIR-18-0174
– volume: 7
  start-page: 283ra252
  year: 2015
  ident: CR26
  article-title: STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
  publication-title: Sci. Transl. Med
– volume: 350
  start-page: 1084
  year: 2015
  end-page: 1089
  ident: CR10
  article-title: Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
  publication-title: Science
  doi: 10.1126/science.aac4255
– volume: 13
  start-page: 25
  year: 2011
  end-page: 36
  ident: CR12
  article-title: Fusobacterium nucleatum in periodontal health and disease
  publication-title: Curr. Issues Mol. Biol.
– volume: 358
  start-page: eaao5610
  year: 2017
  ident: CR33
  article-title: Recurrent infection progressively disables host protection against intestinal inflammation
  publication-title: Science
  doi: 10.1126/science.aao5610
– volume: 170
  start-page: 548
  year: 2017
  end-page: 563 e516
  ident: CR9
  article-title: Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy
  publication-title: Cell
  doi: 10.1016/j.cell.2017.07.008
– volume: 22
  start-page: 299
  year: 2012
  end-page: 306
  ident: CR15
  article-title: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
  publication-title: Genome Res.
  doi: 10.1101/gr.126516.111
– volume: 359
  start-page: 91
  year: 2018
  end-page: 97
  ident: CR11
  article-title: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
  publication-title: Science
  doi: 10.1126/science.aan3706
– volume: 22
  start-page: 5574
  year: 2016
  end-page: 5581
  ident: CR13
  article-title: Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis
  publication-title: Clin. Cancer Res
  doi: 10.1158/1078-0432.CCR-16-1786
– volume: 27
  start-page: 450
  year: 2015
  end-page: 461
  ident: CR2
  article-title: Immune checkpoint blockade: a common denominator approach to cancer therapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.03.001
– volume: 152
  start-page: 851
  year: 2017
  end-page: 866 e824
  ident: CR18
  article-title: Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappab, and up-regulating expression of microRNA-21
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.11.018
– volume: 515
  start-page: 558
  year: 2014
  end-page: 562
  ident: CR5
  article-title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
  publication-title: Nature
  doi: 10.1038/nature13904
– volume: 10
  start-page: 737
  year: 2003
  end-page: 744
  ident: CR35
  article-title: Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients
  publication-title: Cancer Gene Ther.
  doi: 10.1038/sj.cgt.7700634
– volume: 8
  year: 2018
  ident: CR14
  article-title: Increased abundance of clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-18596-0
– volume: 574
  start-page: 45
  year: 2019
  end-page: 56
  ident: CR22
  article-title: Harnessing innate immunity in cancer therapy
  publication-title: Nature
  doi: 10.1038/s41586-019-1593-5
– volume: 9
  start-page: eaak9537
  year: 2017
  ident: CR31
  article-title: Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aak9537
– volume: 22
  start-page: 1499
  year: 2016
  end-page: 1509
  ident: CR23
  article-title: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors
  publication-title: Clin. Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1125
– volume: 14
  start-page: 195
  year: 2013
  end-page: 206
  ident: CR17
  article-title: Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2013.07.012
– volume: 42
  start-page: 1066
  year: 2019
  end-page: 1074
  ident: CR36
  article-title: HNF4alpha downregulation promotes tumor migration and invasion by regulating Ecadherin in renal cell carcinoma
  publication-title: Oncol. Rep.
– volume: 552
  start-page: S61
  year: 2017
  ident: CR1
  article-title: Cancer immunotherapy
  publication-title: Nature
  doi: 10.1038/d41586-017-08699-z
– volume: 373
  start-page: 1627
  year: 2015
  end-page: 1639
  ident: CR3
  article-title: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1507643
– volume: 16
  start-page: 361
  year: 2019
  end-page: 375
  ident: CR7
  article-title: Immunotherapy in colorectal cancer: rationale, challenges and potential
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  doi: 10.1038/s41575-019-0126-x
– volume: 469
  start-page: 102
  year: 2020
  end-page: 110
  ident: CR32
  article-title: Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2019.10.033
– volume: 217
  start-page: e20192282
  year: 2020
  ident: CR29
  article-title: Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20192282
– volume: 20
  start-page: 215
  year: 2016
  end-page: 225
  ident: CR16
  article-title: Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2016.07.006
– volume: 63
  start-page: 3785
  year: 2020
  end-page: 3816
  ident: CR28
  article-title: Targeting stimulator of interferon genes (STING): a medicinal chemistry perspective
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.9b01039
– volume: 22
  start-page: 813
  year: 2016
  end-page: 820
  ident: CR21
  article-title: Microsatellite instability as a biomarker for PD-1 blockade
  publication-title: Clin. Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1678
– volume: 20
  start-page: 142
  year: 2002
  end-page: 152
  ident: CR34
  article-title: Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2002.20.1.142
– volume: 565
  start-page: 600
  year: 2019
  end-page: 605
  ident: CR24
  article-title: A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
  publication-title: Nature
  doi: 10.1038/s41586-019-0878-z
– volume: 369
  start-page: 134
  year: 2013
  end-page: 144
  ident: CR4
  article-title: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1305133
– volume: 65
  start-page: 1973
  year: 2016
  end-page: 1980
  ident: CR19
  article-title: Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
  publication-title: Gut
  doi: 10.1136/gutjnl-2015-310101
– reference: 34934043 - Signal Transduct Target Ther. 2021 Dec 21;6(1):434
SSID ssj0001637754
ssib046561479
ssib044760960
ssib048695610
Score 2.5622706
Snippet Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict...
Abstract Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that...
SourceID doaj
pubmedcentral
proquest
pubmed
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 398
SubjectTerms 692/53/2422
692/699/67/1504
Antitumor activity
Cancer
Cancer Research
CD8 antigen
Cell Biology
Colorectal cancer
Colorectal carcinoma
Fusobacterium nucleatum
Immune checkpoint
Immune response
Immunotherapy
Internal Medicine
Lymphocytes
Medicine
Medicine & Public Health
Oncology
Organoids
Pathology
Patients
PD-1 protein
PD-L1 protein
Supplements
Tumor-infiltrating lymphocytes
γ-Interferon
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqTr1UPFoI0MqVUE-NcB5-HWnLCiGoegCJm2XHE4EqvIjdleDfM-MEykKlXnpL4jwmnrH9jT3-hrE9IFAPUpSt8REdlAbKELQqNWKRylgPfaTdyKc_1dF5e3whL56l-qKYsIEeeKi4fWlFh6ChtZkKHYdP6aOXIkL0gKeZbBvHvGfOVJ5dUQ1Ru427ZERj9mfYW1OgZY3es9BWlncjS__foOXrCMkXy6R59JmssncjbOQHg7hr7A2kdbZxkNBlvr7nX3gO5Mwz5BvsbLKYYSvNLMyLa56IsdjP8QjSJel4xhH0cSDuCN_d82nPf_0oTyoecFz77SPwq8SJy5r6QvxmR8_cvmfnk8Oz70flmDyhjIiB5mVXG69kRAfEQ90grlEGf1sprD10ClU0bWd9W3nfW7Ai1GBlkNHGqEQflYTmA1tJ0wRbjEcTqt5oCJFC2oK2PdRC66YNsZdemIJ9o4p0NwM_hiPG6nwB9ehGPbp_6bFgu49qcGMzmjn0zSgZsmqrgn1-KsYGQKsaPsF0ke-xmXWtKdjmoLUnSWibrKwFvlwv6XNJ1OWSdHWZSbYpN1db6YJ9fdT8H7Hywn1j3GBTDm3KZZtyd9v_oyp22Nua7JSCDe0uW5nfLuAjQp95-JSt_AElQgAQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9QwFLagXLggoCyhBRkJcSKqk3g9obKMKgSIQyvNzbJjh1aoSZnMSO2_73seT0YDiFsSZ7HjZ_t7i79HyJuIoD4KVnLtAigoTSy9V7JUgEUqbVzsAu5G_vZdnpzxL3Mxzwa3MYdVbubENFGHoUUb-RHAdMyLK3n1_up3iVmj0LuaU2jcJfeQugxDutR8Wk45VxIR-nQukfZy65XiWpoJPiSbjGyQEA7z0TFMYQiKY95nwxp9NMJ8j6GaNejfTEH5deb5_xc4_TvG8g9Ha1q_Zg_Jgww86fFaUh6RO7F_TPaPe1C6L2_oW5pCQZONfZ-czlYjjPPE47y6pD1yHrslHMX-HKVkpAAbaUT2Cdfe0KGjPz6VXyvqYWX85UKkFz1FNmycTeGbLT6zeELOZp9PP56UOf1CGQBFLcu21k6KACqMi3UDyEhqaLaULjhQK2XQvDWOV851Jhrm62iEF8GEIFkXpIjNU7LXD318TmjQvuq0ij5gUJxXpos1U6rhPnTCMV2QD_gj7dWaYcMi53W6MCx-2jyErDCsBfjITSLFByAloCaChRhchFNZkMNNN9g8EEe7FZuCvJ6KYQihX8T1cVile0zibWsK8mzda1NNcKOtqBm8XO30505Vd0v6i_NE043ZvXilCvJu0_PbaiXXf6PtWqYsyJRNMmWvX_y_FQfkfo0SiIGI5pDsLRer-BJg0dK_SrJ_C6cVBUY
  priority: 102
  providerName: ProQuest
Title Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
URI https://link.springer.com/article/10.1038/s41392-021-00795-x
https://www.ncbi.nlm.nih.gov/pubmed/34795206
https://www.proquest.com/docview/2598833641
https://www.proquest.com/docview/2599179883
https://pubmed.ncbi.nlm.nih.gov/PMC8602417
https://doaj.org/article/590c41649479464395ada50dedae6436
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VVkJcELQ8AmVlJMSJiLz8Om6XXVUrtqqglfZm2WunrdAmaB8SvfDbmfFmWy30wiVRYieZeMb2N_b4M8CHQKA-8CytlPXooJQhdU6KVCIWyZW2ofa0GnlyJk4vq_GUT_eg2K6FiUH7kdIyNtPb6LDPS2xsKU6yQOc3k5qniBsPiLqdrHogBvfjKqIkUrdufUxWqgce7fj5HwKV_8ZG_jVBGvud0TN42gFG1t-I-Bz2QnMIR32Uvp3fso8shnDGsfFDeDzpZsqP4GK0XmJVjVTM6zlriLYYf3jOQnNNil4yRH4sEIGEnd2ytmbnX9KvOXPYuf2wPrCbhhGhNTWI-PkZPbN4AZej4cXgNO12UEg9AqFVOiuUFdyjF2JDUSK4EQpLQAjrLXqGwqtqpm2VW1vroDNXBM0d99p7kdVe8FC-hP2mbcJrYF65vFYyOE9xbU7qOhSZlGXlfM1tphI4oTI1PzckGYZoq-ONdnFlOjUarrMZIsBKR157xEIcJeGZD94GvBQJHG81Yrq6tDTooNGOyKLKE3h_l4y1gKY2bBPadcyjI_VamcCrjQLvJKG1srzI8OVyR7U7ou6mNDfXkWmbNuiqcpnAp60R3IsVZ-9LZTbmZdC8TDQv8-vN_2V_C08KMk6KLdTHsL9arMM7RDor14NHcip7cNDvj7-P8XwyPDv_1osG34ujB3ic_B7-AdPNADc
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbK9gAXBBRooICRgBNRncR27ANCLe1qS7erCm2l3owTO7RCzZZ9iO6f4jcy4012tYC49ZZ3JpkZ-xt7_A0hbzyCei9YzJV1EKBkPi6KXMY5YJFEaesrh6uRTwayd8Y_n4vzDfKrXQuDaZVtmxgaajcqcYx8F2A61sWVPPl4_SPGqlE4u9qW0FiYxbGf_4SQbfLh6AD0-zZNu4fDT724qSoQOwAH07hMlZXCATK3Ps2gw5eK5QD6rbMQLUmneKktT6yttNesSL0WhXDaOckqJ4XP4Ll3yCbPIJTpkM39w8Hpl9aCOc8lxgTLfYlEm6t5MK6kXgKWMAokM6Sgwwp4DIsmQqjarOxhmdqdQA-DyaEpRPwgo4hvmsoC_4LDf2d1_jG1G3rM7gNyv4G6dG9hmw_Jhq8fka29GsL8qzl9R0PyaRjV3yLD7mwCLUtgjp5d0RpZlu0Utnx9gXY5oQBUqUe-C1vO6aiipwdxP6EF9MXfrfP0sqbIv43tN7yzxHvGj8nZrajmCenUo9pvE-pUkVQq94XDNLwi15VPWZ5nvHCVsExFZB9_pLlecHoYZNkOB0bjb6ZxWiM0KwGwch1o-AG6CZBEMOed9bArI7LTqsE0rj8xK0ONyOvlaXBanImxtR_NwjU6MMVlEXm60NpSElzaK1IGD8_X9Lkm6vqZ-vIiEINjPTGe5BF532p-JVZINsiUWdiUAZsywabMzbP_f8Urcrc3POmb_tHg-Dm5l6I1Yhqk3iGd6XjmXwAomxYvG0-g5OttO99vc8tDaw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIiEuCCiPlAKLBJywsrb3eUCoEKKWlqqHVsptWXvXtEJ12jxE89f4dcysHUcBxK23OH5NMjM73-zOfkPI64CgPgiWcO08JCh5SIpCyUQBFkm1caHyuBv565HcO-VfRmK0QX4t98JgWeVyTIwDtR-XOEfeB5iOfXElT_tVWxZxPBh-uLxKsIMUrrQu22k0JnIQFj8hfZu-3x-Art9k2fDzyae9pO0wkHgACrOkzLSTwgNKdyHLIfhLzRQkAM47yJyk17w0jqfOVSYYVmTBiEJ4471klZci5PDcW-S2ykWKPqZGXSjnXEnMDrpjiZSbqxUxrqXpoEucD5I5ktFhLzyG7RMhaW33-LBc96cQa7BMNIPcHyQUyXXbY-BfwPjv-s4_Fnlj7BzeJ_da0Et3Gyt9QDZC_ZBs7daQ8F8s6Fsay1Dj_P4WORnOpzDGRA7p-QWtkW_ZzeBTqM_QQqcUICsNyHzhygUdV_R4kBymtICo_MP5QM9rikzcOJLDO0u8Z_KInN6IYh6TzXpch6eEel2klVah8FiQVyhThYwplfPCV8Ix3SMf8Y-0lw27h0W-7fjFePLdtu5rhWElQFduIiE_gDgBkgjmg3cBDmWP7CzVYNtBYGpXJtsjr7rT4L64JuPqMJ7Ha0zkjMt75EmjtU4S3OQrMgYPV2v6XBN1_Ux9fhYpwrGzGE9Vj7xban4lViw7yLVtbMqCTdloU_Z6-_-_4iW5Ay5nD_ePDp6RuxkaI9ZDmh2yOZvMw3NAZ7PiRXQDSr7dtN_9BjoERjs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fusobacterium+nucleatum+enhances+the+efficacy+of+PD-L1+blockade+in+colorectal+cancer&rft.jtitle=Signal+transduction+and+targeted+therapy&rft.au=Gao%2C+Yaohui&rft.au=Bi%2C+Dexi&rft.au=Xie%2C+Ruting&rft.au=Li%2C+Man&rft.date=2021-11-19&rft.issn=2059-3635&rft.eissn=2059-3635&rft.volume=6&rft.issue=1&rft.spage=398&rft_id=info:doi/10.1038%2Fs41392-021-00795-x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2095-9907&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2095-9907&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2095-9907&client=summon